All posts by imreal

STRmix Now Being Used by Suffolk County Crime Lab, Contra Costa Sheriff’s Office


The Contra Costa County, CA Office of the Sheriff and New York’s Suffolk County Crime Laboratory are the latest U.S. organizations to announce they will use STRmix™ to interpret DNA profiles in criminal investigations.

STRmix™, which was developed in New Zealand and Australia, is sophisticated forensic software that can be used to resolve mixed DNA profiles previously thought to be too complex to interpret.

The addition of the two new organizations brings the total number of forensic labs using STRmix™ nationally to 55. That list includes federal agencies such as the FBI and the Federal Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), as well as numerous state and local organizations throughout the country. In addition, STRmix™ is currently in various stages of installation, validation, and training in more than 60 other U.S. organizations.

The Suffolk County Crime Laboratory provides a wide variety of forensic services to the Suffolk County District Attorney’s Office, the Suffolk County Police Department and all other Police Departments within the county, the New York State Police Department, and the United States Attorney’s Office. Services are also provided to the County Attorney’s Office in civil matters.

The Contra Costa County Office of the Sheriff is the largest law enforcement agency in Contra Costa, with over 1,100 sworn and professional employees dedicated to providing the highest level of law enforcement and customer services. The Office of the Sheriff offers a full range of services to more than 1,000,000 residents in the 715-square-mile county.

Since its introduction in 2012, STRmix™ has been used to interpret DNA evidence in more than 120,000 cases worldwide. It has also been used successfully in numerous U.S. court cases, including 35 successful admissibility hearings.

“Forensic labs using STRmix™ are experiencing a marked increase of usable, interpretable, and admissible DNA results in a wide range of criminal cases, including evidence from guns, other touch evidence, and sexual assault evidence,” explains John Buckleton DSc, FRSNZ, Forensic Scientist at the New Zealand Institute of Environmental Science and Research (ESR) and one of the developers of STRmix™.

Buckleton notes that STRmix™ has proved to be particularly effective in helping to solve cold cases in which evidence originally dismissed as inconclusive has been reprocessed, as well as in supporting exonerations of wrongly convicted individuals through reexamination of inconclusive results in post-conviction cases.

The latest version of STRmix™, STRmix™ v2.7, was introduced in late 2019. STRmix™ v2.7 includes several new features in response to improvements recommended by forensic labs to better address the on-the-job needs they regularly encounter.

DBLR™, an application used with STRmix™, was also introduced last year. DBLR™ allows users to undertake superfast database searches, visualize the value of their DNA mixture evidence, and carry out mixture to mixture matches.

For more information about STRmix™ visit http://www.strmix.com.

Share article on social media or email:

Paladin Capital Group Promotes Tom Clute as its Newest Senior Vice President


Paladin Capital Group, a leading multi-stage venture capital firm based in Washington, DC, is pleased to announce the promotion of Tom Clute to Senior Vice President. Tom is an investment lead for the firm, which invests globally in early stage companies with solutions for cyber security and digital resilience.

Tom’s experience within the cyber landscape and deal sourcing capabilities make him a key team member at Paladin. His unique ability to build relationships and trust with entrepreneurs has helped lead to some of the firm’s successful investments, including Cloud Conformity (acquired by Trend Micro) and PhishMe (acquired by BlackRock), as well as earning the respect of his investment partners.

“Tom is a valuable member of the Paladin team and his promotion to Senior Vice President recognizes his outstanding investment results and our confidence and expectations of his future contributions,” said Michael Steed, Founder and Managing Partner of Paladin.

Tom joined Paladin in 2010 and is actively involved in several portfolio companies including Bugcrowd, Dashbird, Expel, Greynoise, RiskLens, and Secure Code Warrior. His responsibilities include identifying, assessing, and executing on new investment opportunities for the firm as well as active support and oversight for portfolio companies.

About Paladin Capital Group

Paladin Capital Group was founded in 2001 and has offices in Washington DC, New York, Silicon Valley, London, and Luxembourg. As a multi-stage investor, Paladin focuses on best-of-breed companies with technologies, products and services that meet the challenging global cybersecurity and digital infrastructure resilience needs for commercial and government customers. Paladin has over $1 billion in committed capital across multiple funds. For updates, follow us on Twitter and LinkedIn.

Share article on social media or email:

Cecelia Hunt Joins JourneyPure as Chief Operating Officer


News Image

Cecelia will add much value given her extensive experience in building and operating behavioral health companies with other health care entrepreneurs.

JourneyPure, a leader in addiction treatment services, is proud to announce that veteran behavioral healthcare executive Cecelia Hunt has joined the company as Chief Operating Officer.

Cecelia Hunt is a proven behavioral healthcare executive with approximately 25-years of industry experience. As an accomplished Senior Healthcare Executive, Ms. Hunt has a diverse management experience including clinical and business operations, expansion and acquisitions, and business development for multi-site/multi-state Behavioral Health/Mental Health organizations.

“Our JourneyPure team is proud to announce Cecelia Hunt is joining JourneyPure as executive vice president and chief operating officer. Cecelia will add much value given her extensive experience in building and operating behavioral health companies with other health care entrepreneurs. Cecelia is a licensed clinician, has valuable experience in providing and managing behavioral health services, and fits perfectly with our JourneyPure culture and with our focus on generating excellent clinical outcomes.” – Kevin Lee, CEO

Ms. Hunt was previously Chief Operating Officer for Perimeter Healthcare, a private equity-backed behavioral health provider. In this position, Ms. Hunt established and managed operational, clinical, and financial objectives for the multi-state private equity-based organization with psychiatric residential treatment facilities and acute inpatient psychiatric hospitals serving both mental health and co-occurring substance use disorders. Prior to serving at Perimeter Healthcare, Ms. Hunt was Chief Operating Officer and Vice President of Operations at WoodRidge Behavioral Health. In this role, Ms. Hunt implemented targeted strategies and continuous improvements in order to optimize quality of care, ultimately ensuring growth and profitability.

She expanded programs and services by developing partnerships with various healthcare service agencies, and established new service delivery lines. Ms. Hunt has also served in various clinical and executive roles at AmiCare Behavioral Centers, Lighthouse Care Center, and Children’s Comprehensive Services. Ms. Hunt earned a Master of Social Work degree from the University of Alabama, and a Bachelor degree in Social Work from the University of Alabama at Birmingham.

ABOUT JOURNEYPURE

JourneyPure, founded in 2014, is a leading substance abuse and mental health treatment provider for adult men and women with 19 residential and outpatient locations across the southeast. They are recognized nationally for their exceptional outcomes, evidenced based best practices, fully integrated / patient centered care, and most importantly for the dedication they have to their mission of getting people healthy and keeping them healthy. Their aim has been to close the gap between residential treatment and a patient’s return home by offering a full continuum of care. This full continuum may begin with residential or outpatient treatment but will always include JourneyPure Coaching which is a technological solution with a human component; allowing a patient to stay connected to JourneyPure for a year, and ultimately remain accountable to their recovery. The driving force behind JourneyPure remains an eternal compassion to help. To learn more about JourneyPure, please visit http://www.journeypure.com

Share article on social media or email:

SITC Announces Three Recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship


Society for Immunotherapy of Cancer

“The contributions Drs. Chen, Freeman and Sharpe have made to the area of immune checkpoint inhibitors have fundamentally changed the treatment of cancer,” said SITC President Mario Sznol, MD.

The Society for Immunotherapy of Cancer (SITC) is pleased to announce Lieping Chen, MD, PhD, from Yale Cancer Center, Gordon Freeman, PhD, from the Dana-Farber Cancer Institute, and Arlene Sharpe, MD, PhD, from Harvard Medical School, as the 2020 recipients of the Richard V. Smalley, MD, Memorial Award and Lectureship, the society’s highest honor.

The research conducted by Drs. Chen, Freeman and Sharpe formed the foundation for developing immune checkpoint blockade immunotherapies and will be featured during the society’s 35th Anniversary Annual Meeting in November at the Gaylord National Hotel & Convention Center in National Harbor, Md.

“The contributions Drs. Chen, Freeman and Sharpe have made to the area of immune checkpoint inhibitors have fundamentally changed the treatment of cancer,” said SITC President Mario Sznol, MD. “The current success of cancer immunotherapy can be traced back to their foundational mechanistic studies and commitment to translating their findings to the clinic.”

Dr. Chen’s lab studied lymphocyte costimulation and coinhibition and their application in treating human diseases for over 25 years. In 1992, his lab published the first proof-of-concept study showing that manipulation of B7-CD28 family molecules could be used for cancer immunotherapy by introducing B7-1 into tumor cells to enhance tumor immunity.

This study led to additional studies utilizing antibodies targeting CTLA-4, a B7-CD28 family molecule, for the treatment of human cancer. From 1999–2002, Dr. Chen’s lab cloned the B7-H1 (PD-L1) molecule and discovered the PD-1/PD-L1 pathway’s role in the evasion of tumor immunity and established this pathway as a target for cancer immunotherapy.

Dr. Chen will deliver his Richard V. Smalley, MD, Memorial Lectureship, “Why were we interested in immunity within the tumor microenvironment in the 1990s?” at SITC 2020. He explained, “Early in our research, less attention was paid to our work. But then, the most exciting thing we found was that the PD-1/PD-L1 pathway play a key role in cancer escape from immune attack, which led us to investigate further to help development of anti-PD-1/PD-L1 therapy.”

Dr. Chen is the United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology and Medical Oncology at Yale School of Medicine, and co-leader of the Cancer Immunology Program at the Yale Cancer Center. Dr. Chen earned his medical degree from Fujian Medical School and earned his doctorate from Drexel University School of Medicine.

The research conducted by Dr. Freeman’s lab identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). His group’s discovery of PD-L1 and PD-L2 demonstrated that these molecules were ligands for PD-1, thereby defining the PD-1 pathway and the potential of drugs to block these interactions. Dr. Freeman demonstrated that PD-L1 is highly expressed on many solid tumors as well as some hematologic malignancies, which allows these tumors to inhibit immune responses. He made antibodies that blocked the PD-1 pathway and showed they enhanced immune responses.

“The PD-L1/PD-1 Pathway: Discovery and New Insights,” is the title of Dr. Freeman’s Richard V. Smalley, MD, Memorial Lectureship. “This success of PD-L1 and PD-1 immunotherapy has given patients new hope and energized scientists and drug developers as never before. We are finding what works, what’s safest, how it works, and who it will work for,” said Dr. Freeman when describing the impact of his work.

Dr. Freeman is in the Department of Medical Oncology at Dana-Farber Cancer Institute and is a Professor of Medicine at Harvard Medical School. Dr. Freeman earned his bachelor’s degree in biochemistry and molecular biology, and doctorate in microbiology and molecular genetics from Harvard University. Dr. Freeman is a Fellow of the AACR Academy and the recipient of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and the 2017 recipient of the Warren Alpert Foundation award.

Dr. Sharpe has used genetic approaches to discover T cell costimulatory molecules and understand their functions. Her studies with B7 (CD80) deficient mice led to the discovery of B7-2 (CD86) and the realization that it was the major CD28 ligand. Her work on CTLA-4 knockout mice convinced the field that CTLA-4 was a critical inhibitory molecule and a key mediator of T cell tolerance. Her studies of PD-1 and its ligand revealed that the inhibitory functions of this pathway control resolution of inflammation and tolerance in tissues.

Recently, her laboratory has developed a CRISPR/Cas9 screening platform to identify genes that regulate T cell tolerance and T cell exhaustion in immune cells, and is using this approach to determine how perturbation of coinhibitory receptors and other immunoregulatory genes can improve responses to PD-1 checkpoint blockade. Dr. Sharpe will deliver her Richard V. Smalley, MD, Memorial Lectureship titled, “Discovery of New IO Targets and Mechanisms Leveraging CRISPR” discussing her recent work. “The PD-1 story emphasizes the value of discovery and curiosity-driven research,” she says. “This work did not start out to understand how to cure cancer. We were studying how the immune system was regulated, and discovered a key mechanism tumors use to evade immune attack.”

Dr. Sharpe is the George Fabyan Professor of Comparative Pathology, Chair of the Department of Immunology at Harvard Medical School, and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. She is a member of the Department of Pathology at Brigham and Women’s Hospital, a Member of the Broad Institute of MIT and Harvard, Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center. Dr. Sharpe earned her medical degree and doctorate from Harvard Medical School and completed her residency in pathology at Brigham and Women’s Hospital. She is a member of the National Academy of Sciences and the National Academy of Medicine. Dr. Sharpe is the 2014 recipient of the William B. Coley Award for Distinguished Research in Tumor Immunology, the 2017 recipient of the Warren Alpert Foundation Prize for her contributions to the discovery of the PD-1 pathway, and a fellow of the AACR.

The Smalley Memorial Award, established by SITC in 2005 and awarded annually to a clinician or scientist who has significantly contributed to the advancement of research in the field of cancer immunotherapy, is named in honor of the past SITC president and charter member of the society.

Previous recipients of the Smalley Award are: Olivera J. Finn, PhD; Philip D. Greenberg, MD; Paul M. Sondel, MD, PhD; Suzanne L. Topalian, MD; Tasuku Honjo, MD, PhD; Giorgio Trinchieri, MD; Carl H. June, MD; Theresa L. Whiteside, PhD; Ralph M. Steinman, MD; James P. Allison, PhD; Isaiah J. Fidler; DVM, PhD; Giorgio Parmiani, MD; Ernest Borden, MD; Ronald Levy, MD, and Steven A. Rosenberg, MD, PhD.

To learn more about this award, visit SITC CONNECT. Registration is now underway for the 35th Anniversary Annual Meeting (SITC 2020), click here to register, submit research, view sessions and more.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.



Breakthrough Pharmaceutical Laser Drilling Machine with NIR Simplifies Osmotic Drug Delivery


Ackley’s new fully-integrated NIR inspection system represents a significant advancement for the production of osmotic controlled-release drugs. This technology provides increased safety for consumers and additional peace of mind for pharmaceutical manufacturers by offering twice the inspection power.

The VIP Laser Drill + NIR is a precision Class 1 Laser Product designed to drill apertures in the coating of modified-release products to achieve the desired dissolution rate and drug release profile. Built for tablets, caplets and longitudinally compressed tablets (LCT’s) – this single-lane laser drilling system verifies the integrity of a tablet’s outer membrane using two NIR spectrometers, prior to laser drilling and vision inspection. Once a tablet is verified, two CO2 air-cooled lasers drill the correct side of each tablet with one or more apertures. Then, vision inspection confirms each aperture, while Ackley’s patented fail-safe rejection system separates tablets with membrane defects from those with drill defects for further analysis.

This precision laser machine drills and inspects up to 60,000 products per hour. Designed under FDA, cGMP and CE regulations, the VIP Laser + NIR is versatile, affordable and provides effortless continuous operation with minimal user interaction or downtime. Perfect for both pilot and production runs, it features a small footprint, user-friendly touchscreen, multiple recipe management and quick removal change parts.

Learn more and watch the video: https://ackleymachine.com/machines/vip-nir-laser-drilling-machine/

Ackley Machine Corporation designs and manufactures precision machinery to print, laser mark, laser drill, and inspect tablets and capsules of all shapes and sizes. A leader in innovation, Ackley has proudly served the needs of the pharmaceutical, nutraceutical and confectionery industries for nearly 50 years. From R&D to high-volume productions, leading companies and startups trust their brands to Ackley machines. Contact Ackley to see how they can help with your pharmaceutical laser drilling needs today.

Ackley Machine Corporation

https://ackleymachine.com

+1(856) 234 – 3626

sales@ackleymachine.com

Share article on social media or email:

Newcastle Systems Introduces FH Series Mobile Powered Workstation to Meet Increased Healthcare Demand


News Image

Newcastle Systems, a leading provider of mobile-powered workplace solutions designed to make warehouses, manufacturing facilities and retail floors more efficient, today announces their latest product in response to increased demand from healthcare providers amid the COVID-19 pandemic.

The FH Series Mobile Field Health Station is designed to mobilize and power laptops, printers, scanners and other critical devices for 8+ hours at a time at outdoor testing sites, temporary healthcare facilities and more. It also allows healthcare providers to print, test and collect patient data from the bedside, while keeping a safe distance.

“Mobilizing these commonly-used devices will cut down on wasted steps, increase efficiency and a provider’s capacity to service more patients in a timely manner,” said Newcastle CEO John O’Kelly. “Providing a workstation for each employee that can be easily sanitized and used at a safe distance will eliminate the need for shared stations and help facilities protect their employees.”

The FH Series comes standard with an adjustable top antimicrobial HDPE shelf that can be easily wiped down and disinfected. The units are offered with standard 5” or 8” rugged locking casters that accommodate use in parking lots, on gravel or other uneven surfaces, and a swappable lithium battery system for 24/7 operation. Once the battery charge is depleted, it can be easily swapped in seconds with a fully charged battery from the system’s stand-alone charging station. Batteries can be charged in about 4 hours.

“We’ve seen an increased demand over the last few weeks and have worked quickly to create a product that can help our healthcare heroes work as efficiently and safely as possible through the tough weeks to come,” said O’Kelly. “We want to do everything we can to help the helpers. We’re all in this together.”

The FH Series can also be customized with optional accessories to accommodate your current computer and devices, or any combination of scanners, printers, tablet, touchscreen or laptop/keyboard. Additional organization/storage options, shelving, and LED lighting are also available.

To learn more information about the FH Series Mobile Powered Workstation, please contact Newcastle’s sales team 1-781-935-3450 or visit https://www.newcastlesys.com/fh-series-mobile-field-health-testing-stations.

About Newcastle Systems

Newcastle Systems, Inc. is a provider of workplace mobility solutions that include a range of mobile carts for every workstation need with a unique, integrated power system that enables companies to maximize workplace efficiencies with minimal investment. Newcastle Systems mobility solutions are in place around the world helping reduce footsteps in warehouses, speed up receiving, picking and shipping operations, improve staffing efficiencies on retail floor, and provide convenience and ergonomic benefits for employees in manufacturing, education, distribution, military and government sectors. For more information, visit http://www.newcastlesys.com or e-mail sales@newcastlesys.com.

Share article on social media or email:

ERT Offers First Patient-Administered ECG Assessment for Continuation of Clinical Trials during COVID-19


KardiaMobile 6L is a hand-held, patient-administered ECG device

KardiaMobile 6L Device

By combining AliveCor’s advanced technology with our proven software and workflow platform, we are enabling our customers to continue developing new medical treatments during the COVID-19 pandemic, regardless of whether trial patients have physical access to investigative site personnel

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a first-of-its-kind partnership with AliveCor, the leader in AI-based, personal ECG technology. The partnership enables ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.

“By combining AliveCor’s advanced technology with our proven software and workflow platform, we are enabling our customers to continue developing new medical treatments during the COVID-19 pandemic, regardless of whether trial patients have physical access to investigative site personnel,” said Ellen Street, Executive Vice President of Cardiac Safety of ERT. “The device’s ease of use, combined with ERT’s centralized overread and data collection methodology make it an ideal solution for ensuring patient safety during ongoing clinical trials.”

KardiaMobile 6L is a hand-held, 6-lead personal ECG that records Lead II data without the attachment of electrodes. Data captured from the device will be integrated into ERT’s software and workflow platform and read by ERT cardiologists to ensure patient safety during the clinical development of new medical treatments. ERT provides high quality measurements for QTc, QRS, and other ECG intervals that enable efficacy and safety monitoring during clinical trials.

“ERT’s experience in analyzing millions of ECGs and their dedication to patient safety make them the gold standard in clinical trial cardiac safety assessment,” said Priya Abani, CEO of AliveCor. “We look forward to this partnership and to delivering the innovative solutions and valuable data that clinical trial sponsors require.”

Click here to learn more about ERT’s virtual clinical trial capabilities.

About ERT

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.

About AliveCor

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile 6L device is the most clinically validated personal ECG solution in the world. KardiaMobile provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, and Normal rhythm in an ECG. Kardia is the first AI enabled platform to aid patients and clinicians in the early detection of atrial fibrillation, the most common arrhythmia and one associated with a highly elevated risk of stroke. AliveCor’s enterprise platform allows third party providers to manage their patients and customers’ heart conditions simply and profitably using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor was named the No.1 artificial intelligence company in Fast Company’s Top 50 Most Innovative Companies. AliveCor is a privately-held company headquartered in Mountain View, Calif. “Consumer” or “Personal” ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

Share article on social media or email:



ASCCP Announces New President for 2020-21


ASCCP announces its new president, Mark Einstein, MD, MS. Dr. Einstein was sworn in as President of ASCCP at the Annual Business Meeting. In his role as president, he will serve as Executive Officer for ASCCP and oversee the governance of the Board organization. Prior to becoming President, Einstein served as President-Elect.

“Even in these uncertain times, we need to keep our eye on prevention of cervical cancer. ASCCP is committed to our mission and recently launched the ASCCP Risk-Based Management Consensus Guidelines for the management of women with abnormal cervical cancer screening,” said Dr. Einstein.

Dr. Einstein completed his fellowship in Gynecologic Oncology at Albert Einstein College of Medicine in 2002 and is an accomplished surgeon-scientist. He currently serves as Professor and Chair, Department of OB/GYN & Women’s Health at Rutgers New Jersey Medical Center and Interim Chief Medical Officer for University Hospital in Newark, NJ.

_____________________________________________________________________________

About ASCCP

ASCCP is a professional society for an interdisciplinary group of healthcare professionals including physicians, physician assistants, nurse practitioners, midwives and researchers, who are focused on improving lives through the prevention and treatment of anogenital and HPV-related diseases. For more information visit http://www.asccp.org.

Share article on social media or email:

OLEO Releases New Boost+ CBD Drink Mix for On-The-Go Recovery


The first single-serving flavorless CBD supplement that adds a boost of OleoCBD™ to any hot or cold beverage

OLEO™ CBD Boost +

“We love hearing from customers about what products they want to see us launch next. This one has been requested over and over, so we’re finally making it happen!,” said Skyler Bissell, CEO and Co-Founder of OLEO, Inc.

OLEO, Inc., creator of the most effective CBD supplement for fitness recovery, is excited to announce the launch of OLEO™ CBD Boost + — the first single-serving flavorless CBD supplement that adds a boost of OleoCBD™ to any hot or cold beverage or recipe. As the most versatile grab-and-go essential for active lifestyle enthusiasts, CBD Boost + is a prepackaged, premeasured, and 100% water-soluble flavorless CBD powder with 25mg of OleoCBD™. Quickly and easily add one packet of CBD Boost + into any refreshment before or after physical activity to renew the body, revive the mind, and reach peak performance.

“We love hearing from customers about what products they want to see us launch next. This one has been requested over and over, so we’re finally making it happen!,” said Skyler Bissell, CEO and Co-Founder of OLEO, Inc. “2020 is going to be a big year for us and I’m excited for everyone to see the new projects we have in the works. OLEO is about more than just building products, it’s about creating a community and helping people live better lives.”

Founded in 2015 in Seattle, OLEO™ is North America’s leading purveyor of powdered CBD drink mixes for a healthy, active lifestyle. Using its own proprietary and patent-pending micro-encapsulation technology, OLEO™ converts pure CBD oil into a water-soluble powder known as OleoCBD™. This technology ensures that OLEO™ and Powered by OLEO™ partner products offer double the bioaccessibility of regular CBD, meaning higher quantities of cannabidiol can be absorbed by the body. The micro-encapsulation process additionally removes any bitter aftertaste, allowing both the flavored and non-flavored drink mixes to have a clean, pleasant taste compared to typical CBD tinctures.

In addition to the new CBD Boost + on-the-go packets, OLEO™ drink mixes are also available in a variety of flavorless and flavored multi-serving jars and single-serving packets that combine the benefits of 25mg of OleoCBD™ per serving with the power of functional ingredients such as freeze-dried coconut water and real rooibos and black tea, available with or without caffeine to either energize or unwind. All of OLEO™’s drink mixes dissolve quickly in cold or hot water, making them easy to consume at any point throughout the day, helping support full body recovery after an active day. The entire product line not only offers consistent made-in-the-USA quality, but is also guaranteed to be 100% THC-free with zero intoxicating effects. It’s hydration without the high.

OLEO™ CBD Boost + is available now for purchase online and at key retailers in the United States. For more information on OLEO, Inc., OleoCBD™, and Powered by OLEO™, please visit OLEOlife.com.

About OLEO, Inc.

OLEO, Inc. is a consumer-packaged goods company thoughtfully designing potent, water-soluble CBD products for the active lifestyle community. OLEO offers a collection of powdered beverages infused with their active ingredient OleoCBD™, including CBD Boost +, the new flavorless CBD powder for on-the-go recovery. OleoCBD™ is created with a patent-pending Micro-Encapsulation technology that masks any bitter aftertaste and makes the CBD content two-times more bioaccessible, leading to better absorption and longer lasting effects. OLEO is playing a tremendous role in the advancement of cannabinoid technology, testing standards and consumer product offerings, and helping to make the cannabinoid and hemp industry more trusted, beneficial and approachable for all.

Share article on social media or email:

Spa Revolutions Introduces Affiliate Program For Existing Spa Clients and Free Samples of New On-Demand, Sanitary Thermal Wellness Technology


News Image

Earlier this year, Spa Revolutions’ engineers patented a breakthrough system of four, water-activated thermaBliss® Charges™ that enhance treatments across all areas of spa, beauty, and wellness while eliminating the need for electrical appliances. With roots fifteen years long in the spa and salon industry, the innovative company bringing the patented mineral energy technology to market, has already revolutionized paraffin and heated massage with self-heating and cooling, PerfectSense Paraffin® and thermaBliss® Stones®/Shells®.

Now, with the current state of the industry, they have begun an affiliate program for new and existing clients that affords them a 30% commission as credit toward inventory purchase when their clients purchase at-home spa products. When signing up for the program, affiliates can also receive free samples of the new thermaBliss Charges which allows clients the ability to test the new self-heating technology including in adjacent industries Chiropractic, Physical Therapy and Dental.

The power of new water-activated thermal wellness technology comes in portable, lightweight, appliance-free stick packs that impacts other industries beyond wellness, health, including food service and delivery, outdoor and on the go as well as medical and military. It offers game-changing levels of thermal enhanced treatments to mobile spa operators – the fastest-growing segment of the spa industry, which serves hotel services, in-home/VIP, special events and corporate wellness programs.

All thermaBliss Charges (Level 1.0 Body, Level 2.0 Body, Facial Blend, and Glacial Blend) activate with standard tap water anywhere on planet earth to create professional thermal wellness applications lasting 90+ minutes.

thermaBliss Charge technology delivers cost-effective, on-demand, portable heat featuring:

  • Thermal Wellness Applications lasting up to 90 minutes
  • Sustained mineral energy activated instantly with water
  • No appliance, no battery, electricity-free, flame-free – safe
  • Portable, lightweight & compact
  • Client-exclusive, single-use and sanitary

Enhancement Tools include:

MASSAGE: Lava Shells/Lava Stones/Glacial Shells, ThermaHerbal Poultice

SKINCARE: ThermaFusion Facial Masque, Paraffin Anywhere

MANI/PEDI: PerfectSense Parrafin, Paraffin Anywhere

WAXING: Depilatory Anywhere

The recent thermaBliss Charge technology breakthroughs, powered by LavaGel® have facilitated compact, lightweight stick pack solutions, containing the natural minerals iron, magnesium, and salt for on-demand activation, onsite with tap water. This innovation has enabled the current dynamic expansion of thermal wellness solutions.

The thermaBliss Collection has been awarded Dermascope Magazine’s 2020 Aesthetician’s Choice Awards Best Massage Product and is already embraced by the crème de la crème of the spa marketplace, including marquee properties such as Cal-a-Vie (Travel+Leisure World #2), prestigious Manhattan Mandarin Oriental, and dozens of other standard-setting properties. Spa Revolutions’ is dedicated to empowering credentialed practitioners who share their mutual passion for enhancing the client experience. Globally, over 4,000 leading spas, salons, and wellness centers use thermaBliss thermal wellness enhancements to improve outcomes, delight clients, and increase profits.

                                                                        ###

EDITOR’S NOTE: For more information about Spa Revolutions and to arrange to speak with a company spokesperson, please contact Nancy Trent or Pamela Wadler at 212-966-0024 or pam@trentandcompany.com.

Share article on social media or email: